Anteris Technologies Global (NASDAQ:AVR) Stock Rating Reaffirmed as “Overweight” by Cantor Fitzgerald

Anteris Technologies Global (NASDAQ:AVR)‘s stock had its “overweight” rating reiterated by equities research analysts at Cantor Fitzgerald in a report released on Wednesday, Benzinga reports. They currently have a $15.00 target price on the stock. Cantor Fitzgerald’s price target would suggest a potential upside of 141.16% from the stock’s current price.

AVR has been the topic of a number of other reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Anteris Technologies Global in a research report on Wednesday, August 26th. Barclays raised shares of Anteris Technologies Global to a “hold” rating in a research report on Wednesday, October 7th. Three analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $14.00.

Anteris Technologies Global Trading Down 3.6%

Shares of NASDAQ AVR traded down $0.23 during mid-day trading on Wednesday, reaching $6.22. The company had a trading volume of 194,294 shares, compared to its average volume of 1,116,170. The firm has a 50 day simple moving average of $8.32 and a two-hundred day simple moving average of $8.05. The stock has a market cap of $606.20 million, a P/E ratio of -3.19 and a beta of 1.87. Anteris Technologies Global has a 52-week low of $3.30 and a 52-week high of $11.06.

Anteris Technologies Global (NASDAQ:AVR) last posted its earnings results on Tuesday, August 11th. The company reported ($0.30) EPS for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.09). The company had revenue of $1.01 million during the quarter, compared to analysts’ expectations of $1.50 million. Anteris Technologies Global had a negative net margin of 4,619.27% and a negative return on equity of 77.69%. During the same period last year, the business earned ($0.58) earnings per share. On average, equities analysts expect that Anteris Technologies Global will post -1.21 EPS for the current year.

Insider Transactions at Anteris Technologies Global

In other Anteris Technologies Global news, major shareholder L1 Capital Pty Ltd acquired 648,455 shares of the stock in a transaction on Monday, October 5th. The shares were bought at an average cost of $7.51 per share, with a total value of $4,869,897.05. Following the transaction, the insider owned 12,778,380 shares of the company’s stock, valued at approximately $95,965,633.80. This trade represents a 5.35% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Over the last quarter, insiders have acquired 1,554,730 shares of company stock worth $11,694,513 and have sold 3,008,459 shares worth $25,243,576. Insiders own 4.50% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Cetera Investment Advisers lifted its stake in shares of Anteris Technologies Global by 64.7% in the first quarter. Cetera Investment Advisers now owns 16,550 shares of the company’s stock valued at $92,000 after purchasing an additional 6,500 shares during the period. Bank of America Corp DE lifted its stake in shares of Anteris Technologies Global by 12.6% in the first quarter. Bank of America Corp DE now owns 68,755 shares of the company’s stock valued at $382,000 after purchasing an additional 7,688 shares during the period. Legal & General Group Plc acquired a new stake in shares of Anteris Technologies Global in the second quarter valued at about $78,000. Bartlett & CO. Wealth Management LLC lifted its stake in shares of Anteris Technologies Global by 174.5% in the first quarter. Bartlett & CO. Wealth Management LLC now owns 12,900 shares of the company’s stock valued at $79,000 after purchasing an additional 8,200 shares during the period. Finally, Abel Hall LLC acquired a new stake in shares of Anteris Technologies Global in the first quarter valued at about $63,000.

Anteris Technologies Global Company Profile

Anteris Technologies Global is a clinical-stage structural heart company developing technologies intended to treat aortic valve disease. The company’s lead product is the DurAVR transcatheter heart valve, which is designed to replicate the performance characteristics of a healthy human aortic valve and restore more natural blood flow.

Anteris uses its proprietary ADAPT tissue-engineering technology to create heart-valve materials designed for durability and biocompatibility. The company is focused primarily on transcatheter aortic valve replacement and related structural-heart applications, with its products progressing through clinical development and regulatory evaluation rather than broad commercial distribution.

The company has Australian origins and maintains operations and clinical-development activities in both Australia and the United States.